In a nutshell This review summarized recent evidence on alternatives to continuous androgen deprivation therapy (CADT). Authors reported that more high-quality evidence is needed to determine overall benefits of new hormonal treatment approaches compared to ADT. Some background Androgen deprivation therapy (ADT) is a type of hormone therapy that...
Read More
In a nutshell This review examined the relationship between androgen deprivation therapy (ADT) and the risk of stroke. Researchers reported a moderate increase in the risk of stroke among prostate cancer patients undergoing ADT. Some background Androgen deprivation therapy (ADT) is a type of hormone therapy commonly used to treat prostate cancer....
Read More
In a nutshell This study examined enzalutamide (Xtandi) as a treatment option for older men with metastatic castration-resistant prostate cancer. Researchers concluded that enzalutamide is well-tolerated and improves overall survival in older men with advanced prostate cancer. Some background Hormone therapy is commonly used to treat advanced...
Read More
In a nutshell This study investigated a possible relationship between respiratory infections and androgen deprivation therapy (ADT) used to treat prostate cancer. Researchers concluded that the risk of developing respiratory infections increases with hormonal therapy. Some background Androgen deprivation therapy (ADT) is commonly used to treat...
Read More
In a nutshell The authors aimed to determine the change in bone density in patients who received luteinizing hormone-releasing agonists (LHRHa, treatments that reduce testosterone production in the body) compared to estradiol patches (patches that deliver the hormone estradiol). The authors concluded that EPs reduce the loss of bone density and...
Read More
In a nutshell The authors aimed to evaluate the risk of fractures and overall bone health following treatment with aromatase inhibitors. Some background Aromatase inhibitors (AIs) are a class of drug used to treat estrogen receptor positive breast cancer (ER+; breast cancer that is dependent on the hormone estrogen for growth). Their use, however,...
Read More
In a nutshell This phase II trial based in Dallas, Texas aims to determine the effect of immunotherapy and stereotactic ablative body radiation as a metastatic hormone-resistant prostate cancer treatment. The main outcome to be investigated is time from treatment until cancer progression. The details Metastatic prostate cancer is cancer that...
Read MoreIn a nutshell The authors determined the association between beta-blockers and prostate cancer-specific mortality (patients who died from prostate cancer following treatment) in patients with high-risk (stage IV) or metastatic (cancer spread out from prostate) cancer. Some background Hormone therapy is a common treatment used in prostate...
Read More
In a nutshell The authors determined the effect of hormone therapy on hot flash interference in prostate cancer patients. Some background Hormone therapy is a common treatment used in prostate cancer. It involves targeting the male sex hormones active in prostate cancer, such as testosterone. However, side effects to hormone therapy can...
Read More
In a nutshell The authors determined the effect of radiotherapy as an additional treatment, in patients with node-positive prostate cancer. Some background Radiotherapy is a common treatment used in prostate cancer. It involves directing a beam of radiation at the tumor site to kill cancer cells with minimal damage to...
Read More
In a nutshell The authors determined the safety and effectiveness of abiraterone acetate (Zytiga) in patients with metastatic hormone-resistant prostate cancer. Some background Hormone therapy is a common treatment used in prostate cancer. It targets the male sex hormones active in prostate cancer, such as testosterone. Some patients...
Read More
In a nutshell The authors identified treatments available for men with advanced prostate cancer who were resistant to hormone therapy (castration-resistant). Some background Hormone therapy is a standard treatment for prostate cancer. It targets the male sex hormones active in prostate cancer, such as testosterone. Some patients...
Read More
